Company profile
UK company 07659324, incorporated on 6 June 2011.
ThioLogics is developing a groundbreaking technology platform that will enable the homogeneous modification of native proteins.
Thiologics Limited is a UK company with status active founded in 2011.
Company number 07659324
Reference milestones and recent Companies House filing stream events.
Company registered at Companies House
In 2011 Dr James Baker co-founded Thiologics (www.thiologics.com), to provide a vehicle to translate the Next Generation Maleimide platform for homogeneous protein conjugation towards clinical product development. ThioLogics is a company formed by UCL Business (UCLB) and is in an early pre-seed phase of development supported solely by UCLB funds. The formation of ThioLogics has created a market presence and facilitated early engagement through our existing networks.
ThioLogics develops immunotherapies.
Thiologics is a UCL Business PLC (UCLB) wholly owned company spun-out of UCL Chemistry. The company aims to commercialise new bioconjugation technologies developed in the laboratories of Professor Stephen Caddick and Dr James Baker. ThioLogics is particularly focused on delivering technology that will enable the construction of homogeneous antibody-drug conjugate therapeutics (ADCs). For further information, please contact Dr Chris Williams, Business Development Manager, [email protected].
N/A
Development of novel highly specific linker technologies used in the generation of Antibody-Drug-Conjugates
